製品番号: HY-W012352

2-Hydroxyanthraquinone

カスタマーレビュー

Based on 1 Customer Validation

2-Hydroxyanthraquinone is a product generated by the photochemical oxidation of Anthracene (ANT) (HY-Y0299). 2-Hydroxyanthraquinone induces ferroptosis in cardiomyocytes by depleting GSH and inhibiting GPX4, leading to cardiac developmental malformations. 2-Hydroxyanthraquinone causes damage to the cerebrovascular system and blood-brain barrier in zebrafish by downregulating the Wnt/β-catenin signaling pathway, as well as inducing inflammation and neuronal apoptosis. 2-Hydroxyanthraquinone can be used in studies related to cerebrovascular diseases and cardiotoxicity.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.0%
CAS 番号: 605-32-3
分子式: C₁₄H₈O₃
分子量:224.22

保管条件:

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

2-Hydroxyanthraquinone 構造式

CAS 番号: 605-32-3

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- Cellular Effect
- 体外実験
- 体内実験
化学情報
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Glutathione Peroxidase アイソフォーム固有の製品をすべて表示 :

GPX1
GPX4

Wnt アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
DU-145	IC₅₀	72 μM Compound: 5	Cytotoxicity against Homo sapiens (human) DU145 cells assessed as inhibition of cell survival after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) DU145 cells assessed as inhibition of cell survival after 96 hr by MTT assay	10.1007/s00044-012-0197-5
MCF7	IC₅₀	69 μM Compound: 5	Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell survival after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell survival after 96 hr by MTT assay	10.1007/s00044-012-0197-5
NCI-H460	IC₅₀	66 μM Compound: 5	Cytotoxicity against Homo sapiens (human) H460 cells assessed as inhibition of cell survival after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) H460 cells assessed as inhibition of cell survival after 96 hr by MTT assay	10.1007/s00044-012-0197-5

体外実験

2-Hydroxyanthraquinone binds stably to zebrafish GPX4 protein with a binding energy of −8.3 kcal/mol, mediated by amino acid residues Pro-140, Lys-143, and Arg-168^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

2-Hydroxyanthraquinone (0.7-1.9 mg/L; waterborne exposure; 6-60 h) impairs cerebrovascular and blood-brain barrier (BBB) development in zebrafish embryos by simultaneously inducing neuroinflammation and inhibiting the Wnt/β-catenin signaling pathway, thereby triggering apoptotic death of brain cells and persistent motor behavioral abnormalities^[1].
2-Hydroxyanthraquinone (0.4-1.2 mg/L; waterborne exposure; 6-96 h) induces concentration-dependent cardiac developmental toxicity in zebrafish embryos via ferroptosis, including reduced cardiomyocyte proliferation, oxidative stress, lipid metabolism disorder, iron accumulation, and cardiac structural/functional defects^[2].
2-Hydroxyanthraquinone (300-400 µg/L; waterborne exposure; 28 days) induces cardiac injury in adult zebrafish, including ventricular atrophy, cardiomyocyte degeneration, fibrosis, and vacuolization^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

wild-type (AB); transgenic lines Tg (kdrl:mCherry), Tg (mpeg1:GFP), Tg (fli:GFP), Tg (lyz:DsRed), Tg (elavl3:GFP) (embryos at 6 hours post-fertilization)^[1]
Dosage:

0.7 mg/L; 1.3 mg/L; 1.9 mg/L
Administration:

waterborne; daily renewal; 6 hpf to 24 hpf or 60 hpf
Result:

Reduced cerebrovascular area by ~40% relative to controls in medium (1.3 mg/L) and high (1.9 mg/L) dose groups at 24 hpf.
Reduced cerebrovascular area by 50% relative to controls in high dose group at 60 hpf; diminished head size by ~25% in high dose group at 60 hpf; shortened distance between intersegmental vessels at 60 hpf.
Downregulated genes involved in vascular/lymphatic development (itgb4, kdr, kdrl, vegfc, vegfa, flt4) at 60 hpf.
Increased brain microglia by ~40% relative to controls in high dose group.
Increased ROS content by over fourfold relative to controls in high dose group.
Upregulated pro-inflammatory cytokines (il1β, tnf-α, nf-κb, il6, nos2, rela) and downregulated anti-inflammatory il10.
Increased TUNEL-positive brain cells by ~twofold relative to controls in high dose group; upregulated p53 gene expression.
Increased BBB permeability in medium and high dose groups; altered expression of genes related to BBB development (spock1, abcc1, abcg2, abcb4, abcb5).
Reduced β-catenin protein expression to ~one-third of control levels; downregulated pathway target genes (lef1, β-catenin) and upregulated inhibitory genes (dkk1, wif1).
Reduced total movement distance, average swimming speed, movement time, and continuous movement duration by ~75% relative to controls in all dose groups; decreased activity frequency and cumulative activity duration, and increased immobility duration in a concentration-dependent manner.

Animal Model:

wild-type (AB); transgenic Tg (myl7:GFP) (embryos, 6 hours post-fertilization)^[3]
Dosage:

0.4 mg/L; 0.8 mg/L; 1.2 mg/L
Administration:

waterborne; continuous; 6 hpf to 96 hpf
Result:

Caused concentration-dependent increases in zebrafish embryo mortality at 96 hpf.
Reduced body length to ~3500 μm (0.4 mg/L), ~3200 μm (0.8 mg/L), ~2500 μm (1.2 mg/L) vs control ~4000 μm at 96 hpf.
Increased yolk sac area at 96 hpf.
Enlarged pericardial area to ~25000 μm² (0.4 mg/L), ~45000 μm² (0.8 mg/L), ~65000 μm² (1.2 mg/L) vs control ~15000 μm² at 96 hpf.
Decreased heart rate over 20 seconds to ~45 beats (0.4 mg/L), ~35 beats (0.8 mg/L), ~30 beats (1.2 mg/L) vs control ~50 beats at 96 hpf.
Increased sinus venosus-bulbus arteriosus (SV-BA) distance to ~170 μm (0.4 mg/L), ~220 μm (0.8 mg/L), ~250 μm (1.2 mg/L) vs control ~120 μm in transgenic Tg (myl7:GFP) embryos at 96 hpf.
Reduced cardiomyocyte numbers and caused failed cardiac cyclization revealed by H&E staining.
Downregulated expression of cardiac developmental genes myl7, tbx2b, hand2, and upregulated gata4 and nppa.
Reduced cardiomyocyte proliferation by ~50% at 0.8 and 1.2 mg/L, with downregulated expression of proliferation-related genes cdk2, ccne1, and ccnd1.
Significantly elevated ROS levels in the heart, with downregulated expression of antioxidant genes nrf2, cat, sod, and gclm; decreased CAT and GSH activities, and increased SOD and MDA activities.
Increased cardiac lipid content revealed by Oil Red O staining, elevated total cholesterol (TC) at 1.2 mg/L, and dysregulated expression of lipid metabolism genes (scd, fasn, elovl4, elovl5 upregulated; cd36 downregulated).
Increased iron accumulation revealed by FerroOrange staining and tissue iron measurements, with dysregulated ferroptosis-related gene expression: gpx4, slc7a11, slc3a2 downregulated; acsl4 upregulated; iron metabolism genes fht1, tfr1, fpn1, dmt1 altered.
Significantly reduced pericardial area and restored gpx4 gene expression when co-exposed with 0.6 μM Fer-1 compared to 0.8 mg/L 2-Hydroxyanthraquinone alone.

Animal Model:

wild-type (3-month-old adult)^[3]
Dosage:

300 µg/L; 400 µg/L
Administration:

waterborne; daily; 28 days
Result:

Caused ventricular atrophy with ventricular area ~650000 μm² (300 µg/L), ~550000 μm² (400 µg/L) vs control ~700000 μm².
Induced partial cardiomyocyte degeneration in the 300 µg/L group revealed by H&E staining.
Induced partial fibrosis and vacuole formation in the 400 µg/L group revealed by H&E staining.

化学情報

CAS 番号 605-32-3
性状 Solid
分子量 224.22
分子式 C₁₄H₈O₃
Color Yellow to green yellow
SMILES

OC1=CC2=C(C(C3=CC=CC=C3C2=O)=O)C=C1
Structure Classification
- Quinones
- Anthraquinones
- Phenols
- Monophenols
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (445.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.4599 mL

22.2995 mL

44.5991 mL

5 mM

0.8920 mL

4.4599 mL

8.9198 mL

10 mM

0.4460 mL

2.2300 mL

4.4599 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (11.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (11.15 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (282 KB)
SDS (759 KB)
- English - EN (759 KB)
- Français - FR (759 KB)
- Deutsch - DE (759 KB)
- Norwegian - NO (759 KB)
- Español - ES (759 KB)
- Swedish - SV (759 KB)
- Italian - IT (759 KB)
- Korean - KR (759 KB)
- Portuguese - PT (759 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Li H, et al. 2-Hydroxyanthraquinone exposure causes the damage of cerebrovascular and blood brain barrier in zebrafish via inducing inflammation and downregulation of the Wnt/β-catenin signaling pathway. Comp Biochem Physiol C Toxicol Pharmacol. 2026 Mar;301:110432.
[Content Brief]

[2]. Wang Z, et al. 2-Hydroxyanthraquinone induces cardiotoxicity in zebrafish via ferroptosis. Aquat Toxicol. 2025 Sep;286:107485.
[Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.4599 mL	22.2995 mL	44.5991 mL	111.4976 mL
	5 mM	0.8920 mL	4.4599 mL	8.9198 mL	22.2995 mL
	10 mM	0.4460 mL	2.2300 mL	4.4599 mL	11.1498 mL
	15 mM	0.2973 mL	1.4866 mL	2.9733 mL	7.4332 mL
	20 mM	0.2230 mL	1.1150 mL	2.2300 mL	5.5749 mL
	25 mM	0.1784 mL	0.8920 mL	1.7840 mL	4.4599 mL
	30 mM	0.1487 mL	0.7433 mL	1.4866 mL	3.7166 mL
	40 mM	0.1115 mL	0.5575 mL	1.1150 mL	2.7874 mL
	50 mM	0.0892 mL	0.4460 mL	0.8920 mL	2.2300 mL
	60 mM	0.0743 mL	0.3717 mL	0.7433 mL	1.8583 mL
	80 mM	0.0557 mL	0.2787 mL	0.5575 mL	1.3937 mL
	100 mM	0.0446 mL	0.2230 mL	0.4460 mL	1.1150 mL

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

2-Hydroxyanthraquinone

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Natural Product Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Ferroptosis Compound Library

Phenols Library

Cytoskeleton Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cuproptosis Compound Library

Cancer Stem Cells Compound Library

Antihypertensive Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Extracellular Vesicles (EVs) Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Quinones Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Glutathione Peroxidase アイソフォーム固有の製品をすべて表示

Wnt アイソフォーム固有の製品をすべて表示

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

2-Hydroxyanthraquinone 関連分類

HY-W012352 関連分類